Iskra Pusic MD

Oncology•Saint Louis, MO

Hematologic Oncology

Assistant Professor, Internal Medicine, Medical Oncology, Washington University School of Medicine

Join to View Full Profile

4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 314-454-8304
Fax+1 314-454-5902

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2001 - 2004
University of Zagreb Faculty of MedicineClass of 1997

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2008 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 1
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2025-03-27
1 citations
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.
Joseph Pidala, Jongphil Kim, Denise Kalos, Corey Cutler, Zachariah DeFilipp
Blood Advances. 2025-03-11
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
Leukemia. 2025-01-01

Abstracts/Posters

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Iskra Pusic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Mild Covid-19 Gives Longer Lasting Immunity Than Previously Believed, Claims StudyMay 28th, 2021
$3.4 Million Aids Effort to Make a Better Flu VaccineFebruary 28th, 2019